#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Aggregatibacter actinomycetemcomitans is a Gram-negative member of the human oral microbiota and is involved in human infections and diseases .
2-1	16-31	Aggregatibacter	person[2]	new[2]	coref	2-4[3_2]
2-2	32-53	actinomycetemcomitans	person[2]	new[2]	_	_
2-3	54-56	is	_	_	_	_
2-4	57-58	a	person[3]	giv[3]	coref	4-1[13_3]
2-5	59-72	Gram-negative	person[3]	giv[3]	_	_
2-6	73-79	member	person[3]	giv[3]	_	_
2-7	80-82	of	person[3]	giv[3]	_	_
2-8	83-86	the	person[3]|object[4]	giv[3]|new[4]	_	_
2-9	87-92	human	person[3]|object[4]	giv[3]|new[4]	_	_
2-10	93-97	oral	person[3]|object[4]	giv[3]|new[4]	_	_
2-11	98-108	microbiota	person[3]|object[4]	giv[3]|new[4]	_	_
2-12	109-112	and	_	_	_	_
2-13	113-115	is	_	_	_	_
2-14	116-124	involved	_	_	_	_
2-15	125-127	in	_	_	_	_
2-16	128-133	human	abstract[5]	new[5]	_	_
2-17	134-144	infections	abstract[5]	new[5]	_	_
2-18	145-148	and	_	_	_	_
2-19	149-157	diseases	abstract	new	coref	3-3[8_0]
2-20	158-159	.	_	_	_	_

#Text=One of these diseases is periodontitis , characterized by destruction of tooth-supporting periodontal tissues due to an inflammatory response .
3-1	160-163	One	abstract[7]	new[7]	coref	3-6[0_7]
3-2	164-166	of	abstract[7]	new[7]	_	_
3-3	167-172	these	abstract[7]|abstract[8]	new[7]|giv[8]	_	_
3-4	173-181	diseases	abstract[7]|abstract[8]	new[7]|giv[8]	_	_
3-5	182-184	is	_	_	_	_
3-6	185-198	periodontitis	abstract	giv	coref	6-28[39_0]
3-7	199-200	,	_	_	_	_
3-8	201-214	characterized	_	_	_	_
3-9	215-217	by	_	_	_	_
3-10	218-229	destruction	event[10]	new[10]	_	_
3-11	230-232	of	event[10]	new[10]	_	_
3-12	233-249	tooth-supporting	event[10]	new[10]	_	_
3-13	250-261	periodontal	event[10]|object[11]	new[10]|new[11]	_	_
3-14	262-269	tissues	event[10]|object[11]	new[10]|new[11]	_	_
3-15	270-273	due	event[10]|object[11]	new[10]|new[11]	_	_
3-16	274-276	to	_	_	_	_
3-17	277-279	an	abstract[12]	new[12]	coref	5-8[24_12]
3-18	280-292	inflammatory	abstract[12]	new[12]	_	_
3-19	293-301	response	abstract[12]	new[12]	_	_
3-20	302-303	.	_	_	_	_

#Text=A. actinomycetemcomitans possesses several virulence factors , of which the production of the RTX ( repeats-in-toxin ) leukotoxin ( LtxA ) has received much attention .
4-1	304-306	A.	person[13]	giv[13]	coref	7-21[0_13]
4-2	307-328	actinomycetemcomitans	person[13]	giv[13]	_	_
4-3	329-338	possesses	_	_	_	_
4-4	339-346	several	abstract[15]	new[15]	coref	16-50[132_15]
4-5	347-356	virulence	abstract|abstract[15]	new|new[15]	coref	7-35[49_0]
4-6	357-364	factors	abstract[15]	new[15]	_	_
4-7	365-366	,	_	_	_	_
4-8	367-369	of	_	_	_	_
4-9	370-375	which	_	_	_	_
4-10	376-379	the	abstract[16]	new[16]	coref	16-17[0_16]
4-11	380-390	production	abstract[16]	new[16]	_	_
4-12	391-393	of	abstract[16]	new[16]	_	_
4-13	394-397	the	abstract[16]|object[17]	new[16]|new[17]	_	_
4-14	398-401	RTX	abstract[16]|object[17]	new[16]|new[17]	_	_
4-15	402-403	(	abstract[16]	new[16]	_	_
4-16	404-420	repeats-in-toxin	abstract[16]	new[16]	_	_
4-17	421-422	)	abstract[16]	new[16]	_	_
4-18	423-433	leukotoxin	abstract[16]	new[16]	_	_
4-19	434-435	(	_	_	_	_
4-20	436-440	LtxA	object	new	coref	5-1
4-21	441-442	)	_	_	_	_
4-22	443-446	has	_	_	_	_
4-23	447-455	received	_	_	_	_
4-24	456-460	much	abstract[19]	new[19]	_	_
4-25	461-470	attention	abstract[19]	new[19]	_	_
4-26	471-472	.	_	_	_	_

#Text=LtxA induces cell lysis , degranulation and an inflammatory response in human leukocytes by interaction with the β2-integrins in the cell membrane of human immune cells .
5-1	473-477	LtxA	abstract	giv	coref	6-10
5-2	478-485	induces	_	_	_	_
5-3	486-490	cell	place|abstract[22]	new|new[22]	coref|coref	11-8|11-9[0_22]
5-4	491-496	lysis	abstract[22]	new[22]	_	_
5-5	497-498	,	_	_	_	_
5-6	499-512	degranulation	event	new	_	_
5-7	513-516	and	_	_	_	_
5-8	517-519	an	abstract[24]	giv[24]	_	_
5-9	520-532	inflammatory	abstract[24]	giv[24]	_	_
5-10	533-541	response	abstract[24]	giv[24]	_	_
5-11	542-544	in	abstract[24]	giv[24]	_	_
5-12	545-550	human	abstract[24]|substance[25]	giv[24]|new[25]	_	_
5-13	551-561	leukocytes	abstract[24]|substance[25]	giv[24]|new[25]	_	_
5-14	562-564	by	_	_	_	_
5-15	565-576	interaction	abstract[26]	new[26]	_	_
5-16	577-581	with	abstract[26]	new[26]	_	_
5-17	582-585	the	abstract[26]|substance[27]	new[26]|new[27]	_	_
5-18	586-598	β2-integrins	abstract[26]|substance[27]	new[26]|new[27]	_	_
5-19	599-601	in	abstract[26]|substance[27]	new[26]|new[27]	_	_
5-20	602-605	the	abstract[26]|substance[27]|place[28]	new[26]|new[27]|new[28]	_	_
5-21	606-610	cell	abstract[26]|substance[27]|place[28]	new[26]|new[27]|new[28]	_	_
5-22	611-619	membrane	abstract[26]|substance[27]|place[28]	new[26]|new[27]|new[28]	_	_
5-23	620-622	of	abstract[26]|substance[27]|place[28]	new[26]|new[27]|new[28]	_	_
5-24	623-628	human	abstract[26]|substance[27]|place[28]|place[29]	new[26]|new[27]|new[28]|new[29]	coref	11-13[78_29]
5-25	629-635	immune	abstract[26]|substance[27]|place[28]|place[29]	new[26]|new[27]|new[28]|new[29]	_	_
5-26	636-641	cells	abstract[26]|substance[27]|place[28]|place[29]	new[26]|new[27]|new[28]|new[29]	_	_
5-27	642-643	.	_	_	_	_

#Text=A 530-bp deletion in the promoter region of the LtxA gene operon was identified in the original JP2 strain , cultured from a young individual diagnosed with juvenile periodontitis .
6-1	644-645	A	abstract[30]	new[30]	coref	7-14[44_30]
6-2	646-652	530-bp	abstract[30]	new[30]	_	_
6-3	653-661	deletion	abstract[30]	new[30]	_	_
6-4	662-664	in	abstract[30]	new[30]	_	_
6-5	665-668	the	abstract[30]|place[32]	new[30]|new[32]	_	_
6-6	669-677	promoter	abstract[30]|person|place[32]	new[30]|new|new[32]	_	_
6-7	678-684	region	abstract[30]|place[32]	new[30]|new[32]	_	_
6-8	685-687	of	abstract[30]|place[32]	new[30]|new[32]	_	_
6-9	688-691	the	abstract[30]|place[32]|abstract[35]	new[30]|new[32]|new[35]	_	_
6-10	692-696	LtxA	abstract[30]|place[32]|object|abstract[35]	new[30]|new[32]|giv|new[35]	coref	11-24[80_0]
6-11	697-701	gene	abstract[30]|place[32]|abstract|abstract[35]	new[30]|new[32]|new|new[35]	_	_
6-12	702-708	operon	abstract[30]|place[32]|abstract[35]	new[30]|new[32]|new[35]	_	_
6-13	709-712	was	_	_	_	_
6-14	713-723	identified	_	_	_	_
6-15	724-726	in	_	_	_	_
6-16	727-730	the	abstract[37]	new[37]	coref	11-41[85_37]
6-17	731-739	original	abstract[37]	new[37]	_	_
6-18	740-743	JP2	abstract|abstract[37]	new|new[37]	_	_
6-19	744-750	strain	abstract[37]	new[37]	_	_
6-20	751-752	,	_	_	_	_
6-21	753-761	cultured	_	_	_	_
6-22	762-766	from	_	_	_	_
6-23	767-768	a	person[38]	new[38]	_	_
6-24	769-774	young	person[38]	new[38]	_	_
6-25	775-785	individual	person[38]	new[38]	_	_
6-26	786-795	diagnosed	_	_	_	_
6-27	796-800	with	_	_	_	_
6-28	801-809	juvenile	abstract[39]	giv[39]	coref	9-27[0_39]
6-29	810-823	periodontitis	abstract[39]	giv[39]	_	_
6-30	824-825	.	_	_	_	_

#Text=This discovery marked the beginning of an era , where the detection of the 530-bp deletion categorized highly leukotoxic A. actinomycetemcomitans strains as a member of the JP2 clone of A. actinomycetemcomitans , possessing enhanced virulence .
7-1	826-830	This	event[40]	new[40]	_	_
7-2	831-840	discovery	event[40]	new[40]	_	_
7-3	841-847	marked	_	_	_	_
7-4	848-851	the	abstract[41]	new[41]	_	_
7-5	852-861	beginning	abstract[41]	new[41]	_	_
7-6	862-864	of	abstract[41]	new[41]	_	_
7-7	865-867	an	abstract[41]|time[42]	new[41]|new[42]	_	_
7-8	868-871	era	abstract[41]|time[42]	new[41]|new[42]	_	_
7-9	872-873	,	_	_	_	_
7-10	874-879	where	_	_	_	_
7-11	880-883	the	abstract[43]	new[43]	_	_
7-12	884-893	detection	abstract[43]	new[43]	_	_
7-13	894-896	of	abstract[43]	new[43]	_	_
7-14	897-900	the	abstract[43]|abstract[44]	new[43]|giv[44]	coref	12-21[92_44]
7-15	901-907	530-bp	abstract[43]|abstract[44]	new[43]|giv[44]	_	_
7-16	908-916	deletion	abstract[43]|abstract[44]	new[43]|giv[44]	_	_
7-17	917-928	categorized	_	_	_	_
7-18	929-935	highly	abstract[46]	new[46]	coref	13-3[99_46]
7-19	936-946	leukotoxic	abstract[46]	new[46]	_	_
7-20	947-949	A.	abstract[46]	new[46]	_	_
7-21	950-971	actinomycetemcomitans	person|abstract[46]	giv|new[46]	coref	7-31[48_0]
7-22	972-979	strains	abstract[46]	new[46]	_	_
7-23	980-982	as	_	_	_	_
7-24	983-984	a	_	_	_	_
7-25	985-991	member	_	_	_	_
7-26	992-994	of	_	_	_	_
7-27	995-998	the	abstract[47]	new[47]	_	_
7-28	999-1002	JP2	abstract[47]	new[47]	_	_
7-29	1003-1008	clone	abstract[47]	new[47]	_	_
7-30	1009-1011	of	abstract[47]	new[47]	_	_
7-31	1012-1014	A.	abstract[47]|person[48]	new[47]|giv[48]	coref	8-15[53_48]
7-32	1015-1036	actinomycetemcomitans	abstract[47]|person[48]	new[47]|giv[48]	_	_
7-33	1037-1038	,	_	_	_	_
7-34	1039-1049	possessing	_	_	_	_
7-35	1050-1058	enhanced	abstract[49]	giv[49]	ana	8-7[0_49]
7-36	1059-1068	virulence	abstract[49]	giv[49]	_	_
7-37	1069-1070	.	_	_	_	_

#Text=Based on in vitro studies , it was reported that the JP2 genotype of A. actinomycetemcomitans has a 10 – 20 fold higher lytic activity than the non-JP2 genotypes of A. actinomycetemcomitans .
8-1	1071-1076	Based	_	_	_	_
8-2	1077-1079	on	_	_	_	_
8-3	1080-1082	in	_	_	_	_
8-4	1083-1088	vitro	event[50]	new[50]	coref	9-3[59_50]
8-5	1089-1096	studies	event[50]	new[50]	_	_
8-6	1097-1098	,	_	_	_	_
8-7	1099-1101	it	abstract	giv	_	_
8-8	1102-1105	was	_	_	_	_
8-9	1106-1114	reported	_	_	_	_
8-10	1115-1119	that	_	_	_	_
8-11	1120-1123	the	abstract[52]	new[52]	coref	9-14[62_52]
8-12	1124-1127	JP2	abstract[52]	new[52]	_	_
8-13	1128-1136	genotype	abstract[52]	new[52]	_	_
8-14	1137-1139	of	abstract[52]	new[52]	_	_
8-15	1140-1142	A.	abstract[52]|person[53]	new[52]|giv[53]	coref	8-31[58_53]
8-16	1143-1164	actinomycetemcomitans	abstract[52]|person[53]	new[52]|giv[53]	_	_
8-17	1165-1168	has	_	_	_	_
8-18	1169-1170	a	abstract[56]	new[56]	coref	15-28[116_56]
8-19	1171-1173	10	place[55]|abstract[56]	new[55]|new[56]	_	_
8-20	1174-1175	–	place[55]|abstract[56]	new[55]|new[56]	_	_
8-21	1176-1178	20	quantity|place[55]|abstract[56]	new|new[55]|new[56]	_	_
8-22	1179-1183	fold	place[55]|abstract[56]	new[55]|new[56]	_	_
8-23	1184-1190	higher	abstract[56]	new[56]	_	_
8-24	1191-1196	lytic	abstract[56]	new[56]	_	_
8-25	1197-1205	activity	abstract[56]	new[56]	_	_
8-26	1206-1210	than	abstract[56]	new[56]	_	_
8-27	1211-1214	the	abstract[56]|abstract[57]	new[56]|new[57]	_	_
8-28	1215-1222	non-JP2	abstract[56]|abstract[57]	new[56]|new[57]	_	_
8-29	1223-1232	genotypes	abstract[56]|abstract[57]	new[56]|new[57]	_	_
8-30	1233-1235	of	abstract[56]|abstract[57]	new[56]|new[57]	_	_
8-31	1236-1238	A.	abstract[56]|abstract[57]|person[58]	new[56]|new[57]|giv[58]	coref	9-18[63_58]
8-32	1239-1260	actinomycetemcomitans	abstract[56]|abstract[57]|person[58]	new[56]|new[57]|giv[58]	_	_
8-33	1261-1262	.	_	_	_	_

#Text=Furthermore , longitudinal clinical studies reported a clear correlation between being carrier of the JP2 genotype of A. actinomycetemcomitans and having an increased risk of developing periodontitis at a young age .
9-1	1263-1274	Furthermore	_	_	_	_
9-2	1275-1276	,	_	_	_	_
9-3	1277-1289	longitudinal	event[59]	giv[59]	coref	10-15[71_59]
9-4	1290-1298	clinical	event[59]	giv[59]	_	_
9-5	1299-1306	studies	event[59]	giv[59]	_	_
9-6	1307-1315	reported	_	_	_	_
9-7	1316-1317	a	abstract[60]	new[60]	_	_
9-8	1318-1323	clear	abstract[60]	new[60]	_	_
9-9	1324-1335	correlation	abstract[60]	new[60]	_	_
9-10	1336-1343	between	_	_	_	_
9-11	1344-1349	being	_	_	_	_
9-12	1350-1357	carrier	organization[61]	new[61]	_	_
9-13	1358-1360	of	organization[61]	new[61]	_	_
9-14	1361-1364	the	organization[61]|abstract[62]	new[61]|giv[62]	_	_
9-15	1365-1368	JP2	organization[61]|abstract[62]	new[61]|giv[62]	_	_
9-16	1369-1377	genotype	organization[61]|abstract[62]	new[61]|giv[62]	_	_
9-17	1378-1380	of	organization[61]|abstract[62]	new[61]|giv[62]	_	_
9-18	1381-1383	A.	organization[61]|abstract[62]|person[63]	new[61]|giv[62]|giv[63]	coref	10-6[68_63]
9-19	1384-1405	actinomycetemcomitans	organization[61]|abstract[62]|person[63]	new[61]|giv[62]|giv[63]	_	_
9-20	1406-1409	and	_	_	_	_
9-21	1410-1416	having	_	_	_	_
9-22	1417-1419	an	abstract[64]	new[64]	_	_
9-23	1420-1429	increased	abstract[64]	new[64]	_	_
9-24	1430-1434	risk	abstract[64]	new[64]	_	_
9-25	1435-1437	of	_	_	_	_
9-26	1438-1448	developing	_	_	_	_
9-27	1449-1462	periodontitis	abstract	giv	_	_
9-28	1463-1465	at	_	_	_	_
9-29	1466-1467	a	abstract[66]	new[66]	_	_
9-30	1468-1473	young	abstract[66]	new[66]	_	_
9-31	1474-1477	age	abstract[66]	new[66]	_	_
9-32	1478-1479	.	_	_	_	_

#Text=Often the leukotoxic potential of A. actinomycetemcomitans is characterized by the leukotoxicity in in vitro studies .
10-1	1480-1485	Often	_	_	_	_
10-2	1486-1489	the	abstract[67]	new[67]	_	_
10-3	1490-1500	leukotoxic	abstract[67]	new[67]	_	_
10-4	1501-1510	potential	abstract[67]	new[67]	_	_
10-5	1511-1513	of	abstract[67]	new[67]	_	_
10-6	1514-1516	A.	abstract[67]|person[68]	new[67]|giv[68]	coref	11-43[0_68]
10-7	1517-1538	actinomycetemcomitans	abstract[67]|person[68]	new[67]|giv[68]	_	_
10-8	1539-1541	is	_	_	_	_
10-9	1542-1555	characterized	_	_	_	_
10-10	1556-1558	by	_	_	_	_
10-11	1559-1562	the	abstract[69]	new[69]	coref	11-1[72_69]
10-12	1563-1576	leukotoxicity	abstract[69]	new[69]	_	_
10-13	1577-1579	in	abstract[69]	new[69]	_	_
10-14	1580-1582	in	abstract[69]	new[69]	_	_
10-15	1583-1588	vitro	abstract[69]|organization|event[71]	new[69]|new|giv[71]	coref	16-2[119_71]
10-16	1589-1596	studies	abstract[69]|event[71]	new[69]|giv[71]	_	_
10-17	1597-1598	.	_	_	_	_

#Text=This leukotoxicity is determined by use of cell lysis assays , where human immune cells are exposed either to the bacteria or to purified LtxA , and most often the leukotoxicity is correlated with the JP2 or non-JP2 genotype of the A. actinomycetemcomitans strain .
11-1	1599-1603	This	abstract[72]	giv[72]	coref	11-30[81_72]
11-2	1604-1617	leukotoxicity	abstract[72]	giv[72]	_	_
11-3	1618-1620	is	_	_	_	_
11-4	1621-1631	determined	_	_	_	_
11-5	1632-1634	by	_	_	_	_
11-6	1635-1638	use	abstract[73]	new[73]	_	_
11-7	1639-1641	of	abstract[73]	new[73]	_	_
11-8	1642-1646	cell	abstract[73]|place|abstract[76]	new[73]|giv|new[76]	coref	13-18
11-9	1647-1652	lysis	abstract[73]|abstract|abstract[76]	new[73]|giv|new[76]	coref	13-19
11-10	1653-1659	assays	abstract[73]|abstract[76]	new[73]|new[76]	_	_
11-11	1660-1661	,	_	_	_	_
11-12	1662-1667	where	_	_	_	_
11-13	1668-1673	human	object[78]	giv[78]	_	_
11-14	1674-1680	immune	abstract|object[78]	new|giv[78]	_	_
11-15	1681-1686	cells	object[78]	giv[78]	_	_
11-16	1687-1690	are	_	_	_	_
11-17	1691-1698	exposed	_	_	_	_
11-18	1699-1705	either	animal[79]	new[79]	_	_
11-19	1706-1708	to	animal[79]	new[79]	_	_
11-20	1709-1712	the	animal[79]	new[79]	_	_
11-21	1713-1721	bacteria	animal[79]	new[79]	_	_
11-22	1722-1724	or	_	_	_	_
11-23	1725-1727	to	_	_	_	_
11-24	1728-1736	purified	object[80]	giv[80]	coref	15-9[113_80]
11-25	1737-1741	LtxA	object[80]	giv[80]	_	_
11-26	1742-1743	,	_	_	_	_
11-27	1744-1747	and	_	_	_	_
11-28	1748-1752	most	_	_	_	_
11-29	1753-1758	often	_	_	_	_
11-30	1759-1762	the	abstract[81]	giv[81]	coref	12-10[88_81]
11-31	1763-1776	leukotoxicity	abstract[81]	giv[81]	_	_
11-32	1777-1779	is	_	_	_	_
11-33	1780-1790	correlated	_	_	_	_
11-34	1791-1795	with	_	_	_	_
11-35	1796-1799	the	abstract[82]	new[82]	_	_
11-36	1800-1803	JP2	abstract[82]	new[82]	_	_
11-37	1804-1806	or	abstract[82]	new[82]	_	_
11-38	1807-1814	non-JP2	abstract[82]	new[82]	_	_
11-39	1815-1823	genotype	abstract[82]	new[82]	_	_
11-40	1824-1826	of	abstract[82]	new[82]	_	_
11-41	1827-1830	the	abstract[82]|abstract[85]	new[82]|giv[85]	ana	12-3[0_85]
11-42	1831-1833	A.	abstract[82]|person|abstract[85]	new[82]|giv|giv[85]	coref	12-14
11-43	1834-1855	actinomycetemcomitans	abstract[82]|person|abstract[85]	new[82]|giv|giv[85]	coref	12-15
11-44	1856-1862	strain	abstract[82]|abstract[85]	new[82]|giv[85]	_	_
11-45	1863-1864	.	_	_	_	_

#Text=Therefore , it has been the common believe that the leukotoxicity of an A. actinomycetemcomitans strain could be explained by the 530-bp deletion , an explanation supported by recent results presented by Sampathkumar and co-workers .
12-1	1865-1874	Therefore	_	_	_	_
12-2	1875-1876	,	_	_	_	_
12-3	1877-1879	it	abstract	giv	coref	12-6[87_0]
12-4	1880-1883	has	_	_	_	_
12-5	1884-1888	been	_	_	_	_
12-6	1889-1892	the	abstract[87]	giv[87]	coref	12-13[91_87]
12-7	1893-1899	common	abstract[87]	giv[87]	_	_
12-8	1900-1907	believe	abstract[87]	giv[87]	_	_
12-9	1908-1912	that	_	_	_	_
12-10	1913-1916	the	abstract[88]	giv[88]	coref	13-11[101_88]
12-11	1917-1930	leukotoxicity	abstract[88]	giv[88]	_	_
12-12	1931-1933	of	abstract[88]	giv[88]	_	_
12-13	1934-1936	an	abstract[88]|abstract[91]	giv[88]|giv[91]	_	_
12-14	1937-1939	A.	abstract[88]|person|abstract[91]	giv[88]|giv|giv[91]	coref	13-3
12-15	1940-1961	actinomycetemcomitans	abstract[88]|person|abstract[91]	giv[88]|giv|giv[91]	coref	13-4
12-16	1962-1968	strain	abstract[88]|abstract[91]	giv[88]|giv[91]	_	_
12-17	1969-1974	could	_	_	_	_
12-18	1975-1977	be	_	_	_	_
12-19	1978-1987	explained	_	_	_	_
12-20	1988-1990	by	_	_	_	_
12-21	1991-1994	the	abstract[92]	giv[92]	appos	12-25[93_92]
12-22	1995-2001	530-bp	abstract[92]	giv[92]	_	_
12-23	2002-2010	deletion	abstract[92]	giv[92]	_	_
12-24	2011-2012	,	_	_	_	_
12-25	2013-2015	an	abstract[93]	giv[93]	coref	13-7[100_93]
12-26	2016-2027	explanation	abstract[93]	giv[93]	_	_
12-27	2028-2037	supported	_	_	_	_
12-28	2038-2040	by	_	_	_	_
12-29	2041-2047	recent	abstract[94]	new[94]	coref	13-15[0_94]
12-30	2048-2055	results	abstract[94]	new[94]	_	_
12-31	2056-2065	presented	_	_	_	_
12-32	2066-2068	by	_	_	_	_
12-33	2069-2081	Sampathkumar	person	new	_	_
12-34	2082-2085	and	_	_	_	_
12-35	2086-2096	co-workers	person	new	_	_
12-36	2097-2098	.	_	_	_	_

#Text=However , A. actinomycetemcomitans strains without the 530-bp deletion with high leukotoxicity according to results obtained by cell lysis assay have been reported on .
13-1	2099-2106	However	_	_	_	_
13-2	2107-2108	,	_	_	_	_
13-3	2109-2111	A.	person|abstract[99]	giv|giv[99]	coref|coref	14-7|14-7[109_99]
13-4	2112-2133	actinomycetemcomitans	person|abstract[99]	giv|giv[99]	coref	14-8
13-5	2134-2141	strains	abstract[99]	giv[99]	_	_
13-6	2142-2149	without	abstract[99]	giv[99]	_	_
13-7	2150-2153	the	abstract[99]|abstract[100]	giv[99]|giv[100]	_	_
13-8	2154-2160	530-bp	abstract[99]|abstract[100]	giv[99]|giv[100]	_	_
13-9	2161-2169	deletion	abstract[99]|abstract[100]	giv[99]|giv[100]	_	_
13-10	2170-2174	with	abstract[99]|abstract[100]	giv[99]|giv[100]	_	_
13-11	2175-2179	high	abstract[99]|abstract[100]|abstract[101]	giv[99]|giv[100]|giv[101]	_	_
13-12	2180-2193	leukotoxicity	abstract[99]|abstract[100]|abstract[101]	giv[99]|giv[100]|giv[101]	_	_
13-13	2194-2203	according	abstract[99]|abstract[100]	giv[99]|giv[100]	_	_
13-14	2204-2206	to	abstract[99]|abstract[100]	giv[99]|giv[100]	_	_
13-15	2207-2214	results	abstract[99]|abstract[100]|abstract	giv[99]|giv[100]|giv	coref	18-7[151_0]
13-16	2215-2223	obtained	_	_	_	_
13-17	2224-2226	by	_	_	_	_
13-18	2227-2231	cell	place|abstract[105]	giv|new[105]	coref	16-30[127_105]
13-19	2232-2237	lysis	abstract|abstract[105]	giv|new[105]	_	_
13-20	2238-2243	assay	abstract[105]	new[105]	_	_
13-21	2244-2248	have	_	_	_	_
13-22	2249-2253	been	_	_	_	_
13-23	2254-2262	reported	_	_	_	_
13-24	2263-2265	on	_	_	_	_
13-25	2266-2267	.	_	_	_	_

#Text=Furthermore , the leukotoxic potential of A. actinomycetemcomitans strains has been explained by different mechanisms .
14-1	2268-2279	Furthermore	_	_	_	_
14-2	2280-2281	,	_	_	_	_
14-3	2282-2285	the	abstract[106]	new[106]	coref	15-18[114_106]
14-4	2286-2296	leukotoxic	abstract[106]	new[106]	_	_
14-5	2297-2306	potential	abstract[106]	new[106]	_	_
14-6	2307-2309	of	abstract[106]	new[106]	_	_
14-7	2310-2312	A.	abstract[106]|person|abstract[109]	new[106]|giv|giv[109]	coref|coref	17-18|17-31[142_109]
14-8	2313-2334	actinomycetemcomitans	abstract[106]|person|abstract[109]	new[106]|giv|giv[109]	coref	15-33[118_0]
14-9	2335-2342	strains	abstract[106]|abstract[109]	new[106]|giv[109]	_	_
14-10	2343-2346	has	_	_	_	_
14-11	2347-2351	been	_	_	_	_
14-12	2352-2361	explained	_	_	_	_
14-13	2362-2364	by	_	_	_	_
14-14	2365-2374	different	abstract[110]	new[110]	_	_
14-15	2375-2385	mechanisms	abstract[110]	new[110]	_	_
14-16	2386-2387	.	_	_	_	_

#Text=A higher expression of the mRNA , encoding the ltxA , has been reported to correspond with a higher leukotoxic potential , but also a variation in the activity of LtxA in some A. actinomycetemcomitans has been reported .
15-1	2388-2389	A	abstract[111]	new[111]	coref	16-13[123_111]
15-2	2390-2396	higher	abstract[111]	new[111]	_	_
15-3	2397-2407	expression	abstract[111]	new[111]	_	_
15-4	2408-2410	of	abstract[111]	new[111]	_	_
15-5	2411-2414	the	abstract[111]|object[112]	new[111]|new[112]	coref	16-38[0_112]
15-6	2415-2419	mRNA	abstract[111]|object[112]	new[111]|new[112]	_	_
15-7	2420-2421	,	_	_	_	_
15-8	2422-2430	encoding	_	_	_	_
15-9	2431-2434	the	abstract[113]	giv[113]	coref	15-31[0_113]
15-10	2435-2439	ltxA	abstract[113]	giv[113]	_	_
15-11	2440-2441	,	_	_	_	_
15-12	2442-2445	has	_	_	_	_
15-13	2446-2450	been	_	_	_	_
15-14	2451-2459	reported	_	_	_	_
15-15	2460-2462	to	_	_	_	_
15-16	2463-2473	correspond	_	_	_	_
15-17	2474-2478	with	_	_	_	_
15-18	2479-2480	a	abstract[114]	giv[114]	coref	18-28[159_114]
15-19	2481-2487	higher	abstract[114]	giv[114]	_	_
15-20	2488-2498	leukotoxic	abstract[114]	giv[114]	_	_
15-21	2499-2508	potential	abstract[114]	giv[114]	_	_
15-22	2509-2510	,	_	_	_	_
15-23	2511-2514	but	_	_	_	_
15-24	2515-2519	also	_	_	_	_
15-25	2520-2521	a	abstract[115]	new[115]	_	_
15-26	2522-2531	variation	abstract[115]	new[115]	_	_
15-27	2532-2534	in	abstract[115]	new[115]	_	_
15-28	2535-2538	the	abstract[115]|abstract[116]	new[115]|giv[116]	_	_
15-29	2539-2547	activity	abstract[115]|abstract[116]	new[115]|giv[116]	_	_
15-30	2548-2550	of	abstract[115]|abstract[116]	new[115]|giv[116]	_	_
15-31	2551-2555	LtxA	abstract[115]|abstract[116]|abstract	new[115]|giv[116]|giv	coref	16-14
15-32	2556-2558	in	_	_	_	_
15-33	2559-2563	some	person[118]	giv[118]	coref	16-10[121_118]
15-34	2564-2566	A.	person[118]	giv[118]	_	_
15-35	2567-2588	actinomycetemcomitans	person[118]	giv[118]	_	_
15-36	2589-2592	has	_	_	_	_
15-37	2593-2597	been	_	_	_	_
15-38	2598-2606	reported	_	_	_	_
15-39	2607-2608	.	_	_	_	_

#Text=Only a few studies have compared the leukotoxicity of A. actinomycetemcomitans with the LtxA expression and production defined as a quantification of the LtxA , e. g. , by enzyme-linked immunosorbent assay ( ELISA ) , or mRNA coding for LtxA , but it seems reasonable to assume that the two factors are related .
16-1	2609-2613	Only	_	_	_	_
16-2	2614-2615	a	event[119]	giv[119]	_	_
16-3	2616-2619	few	event[119]	giv[119]	_	_
16-4	2620-2627	studies	event[119]	giv[119]	_	_
16-5	2628-2632	have	_	_	_	_
16-6	2633-2641	compared	_	_	_	_
16-7	2642-2645	the	abstract[120]	new[120]	_	_
16-8	2646-2659	leukotoxicity	abstract[120]	new[120]	_	_
16-9	2660-2662	of	abstract[120]	new[120]	_	_
16-10	2663-2665	A.	abstract[120]|person[121]	new[120]|giv[121]	_	_
16-11	2666-2687	actinomycetemcomitans	abstract[120]|person[121]	new[120]|giv[121]	_	_
16-12	2688-2692	with	abstract[120]|person[121]	new[120]|giv[121]	_	_
16-13	2693-2696	the	abstract[120]|person[121]|abstract[123]	new[120]|giv[121]|giv[123]	coref	17-41[146_123]
16-14	2697-2701	LtxA	abstract[120]|person[121]|object|abstract[123]	new[120]|giv[121]|giv|giv[123]	coref	16-23[125_0]
16-15	2702-2712	expression	abstract[120]|person[121]|abstract[123]	new[120]|giv[121]|giv[123]	_	_
16-16	2713-2716	and	abstract[120]|person[121]	new[120]|giv[121]	_	_
16-17	2717-2727	production	abstract[120]|person[121]|abstract	new[120]|giv[121]|giv	_	_
16-18	2728-2735	defined	_	_	_	_
16-19	2736-2738	as	_	_	_	_
16-20	2739-2740	a	_	_	_	_
16-21	2741-2755	quantification	_	_	_	_
16-22	2756-2758	of	_	_	_	_
16-23	2759-2762	the	object[125]	giv[125]	coref	16-41[0_125]
16-24	2763-2767	LtxA	object[125]	giv[125]	_	_
16-25	2768-2769	,	_	_	_	_
16-26	2770-2772	e.	_	_	_	_
16-27	2773-2775	g.	_	_	_	_
16-28	2776-2777	,	_	_	_	_
16-29	2778-2780	by	_	_	_	_
16-30	2781-2794	enzyme-linked	abstract[127]	giv[127]	ana	16-44[0_127]
16-31	2795-2808	immunosorbent	abstract|abstract[127]	new|giv[127]	_	_
16-32	2809-2814	assay	abstract[127]	giv[127]	_	_
16-33	2815-2816	(	_	_	_	_
16-34	2817-2822	ELISA	person	new	coref	17-38
16-35	2823-2824	)	_	_	_	_
16-36	2825-2826	,	_	_	_	_
16-37	2827-2829	or	_	_	_	_
16-38	2830-2834	mRNA	object	giv	coref	17-47
16-39	2835-2841	coding	_	_	_	_
16-40	2842-2845	for	_	_	_	_
16-41	2846-2850	LtxA	object	giv	coref	17-28
16-42	2851-2852	,	_	_	_	_
16-43	2853-2856	but	_	_	_	_
16-44	2857-2859	it	abstract	giv	coref	17-46[149_0]
16-45	2860-2865	seems	_	_	_	_
16-46	2866-2876	reasonable	_	_	_	_
16-47	2877-2879	to	_	_	_	_
16-48	2880-2886	assume	_	_	_	_
16-49	2887-2891	that	_	_	_	_
16-50	2892-2895	the	abstract[132]	giv[132]	_	_
16-51	2896-2899	two	abstract[132]	giv[132]	_	_
16-52	2900-2907	factors	abstract[132]	giv[132]	_	_
16-53	2908-2911	are	_	_	_	_
16-54	2912-2919	related	_	_	_	_
16-55	2920-2921	.	_	_	_	_

#Text=In the present study , we aimed to investigate if the leukotoxicity of a collection of Ghanaian A. actinomycetemcomitans , serotype b , is related to the LtxA production of the strains determined by Western blotting and ELISA , and LtxA expression as determined in a mRNA expression assay .
17-1	2922-2924	In	_	_	_	_
17-2	2925-2928	the	abstract[133]	new[133]	_	_
17-3	2929-2936	present	abstract[133]	new[133]	_	_
17-4	2937-2942	study	abstract[133]	new[133]	_	_
17-5	2943-2944	,	_	_	_	_
17-6	2945-2947	we	person	acc	ana	18-3
17-7	2948-2953	aimed	_	_	_	_
17-8	2954-2956	to	_	_	_	_
17-9	2957-2968	investigate	_	_	_	_
17-10	2969-2971	if	_	_	_	_
17-11	2972-2975	the	abstract[135]	new[135]	_	_
17-12	2976-2989	leukotoxicity	abstract[135]	new[135]	_	_
17-13	2990-2992	of	abstract[135]	new[135]	_	_
17-14	2993-2994	a	abstract[135]|object[136]	new[135]|new[136]	_	_
17-15	2995-3005	collection	abstract[135]|object[136]	new[135]|new[136]	_	_
17-16	3006-3008	of	abstract[135]|object[136]	new[135]|new[136]	_	_
17-17	3009-3017	Ghanaian	abstract[135]|object[136]	new[135]|new[136]	_	_
17-18	3018-3020	A.	abstract[135]|object[136]|person	new[135]|new[136]|giv	coref	18-37
17-19	3021-3042	actinomycetemcomitans	abstract[135]|object[136]	new[135]|new[136]	_	_
17-20	3043-3044	,	_	_	_	_
17-21	3045-3053	serotype	abstract|object[139]	new|new[139]	_	_
17-22	3054-3055	b	object[139]	new[139]	_	_
17-23	3056-3057	,	_	_	_	_
17-24	3058-3060	is	_	_	_	_
17-25	3061-3068	related	_	_	_	_
17-26	3069-3071	to	_	_	_	_
17-27	3072-3075	the	quantity[141]	new[141]	_	_
17-28	3076-3080	LtxA	abstract|quantity[141]	giv|new[141]	coref	18-32
17-29	3081-3091	production	quantity[141]	new[141]	_	_
17-30	3092-3094	of	quantity[141]	new[141]	_	_
17-31	3095-3098	the	quantity[141]|abstract[142]	new[141]|giv[142]	_	_
17-32	3099-3106	strains	quantity[141]|abstract[142]	new[141]|giv[142]	_	_
17-33	3107-3117	determined	_	_	_	_
17-34	3118-3120	by	_	_	_	_
17-35	3121-3128	Western	object[143]	new[143]	_	_
17-36	3129-3137	blotting	object[143]	new[143]	_	_
17-37	3138-3141	and	_	_	_	_
17-38	3142-3147	ELISA	abstract	giv	coref	18-11
17-39	3148-3149	,	_	_	_	_
17-40	3150-3153	and	_	_	_	_
17-41	3154-3158	LtxA	person|abstract[146]	new|giv[146]	coref	17-48[0_146]
17-42	3159-3169	expression	abstract[146]	giv[146]	_	_
17-43	3170-3172	as	_	_	_	_
17-44	3173-3183	determined	_	_	_	_
17-45	3184-3186	in	_	_	_	_
17-46	3187-3188	a	abstract[149]	giv[149]	coref	18-13[155_149]
17-47	3189-3193	mRNA	object|abstract[149]	giv|giv[149]	coref	18-13
17-48	3194-3204	expression	abstract|abstract[149]	giv|giv[149]	coref	18-14
17-49	3205-3210	assay	abstract[149]	giv[149]	_	_
17-50	3211-3212	.	_	_	_	_

#Text=Furthermore , we wanted to compare the results obtained by ELISA and mRNA expression assay to elucidate the relationship between the two quantification methods used to determine leukotoxic potential as the LtxA production and expression of A. actinomycetemcomitans , respectively .
18-1	3213-3224	Furthermore	_	_	_	_
18-2	3225-3226	,	_	_	_	_
18-3	3227-3229	we	person	giv	_	_
18-4	3230-3236	wanted	_	_	_	_
18-5	3237-3239	to	_	_	_	_
18-6	3240-3247	compare	_	_	_	_
18-7	3248-3251	the	abstract[151]	giv[151]	_	_
18-8	3252-3259	results	abstract[151]	giv[151]	_	_
18-9	3260-3268	obtained	_	_	_	_
18-10	3269-3271	by	_	_	_	_
18-11	3272-3277	ELISA	abstract	giv	_	_
18-12	3278-3281	and	_	_	_	_
18-13	3282-3286	mRNA	abstract|abstract[155]	giv|giv[155]	_	_
18-14	3287-3297	expression	abstract|abstract[155]	giv|giv[155]	_	_
18-15	3298-3303	assay	abstract[155]	giv[155]	_	_
18-16	3304-3306	to	_	_	_	_
18-17	3307-3316	elucidate	_	_	_	_
18-18	3317-3320	the	abstract[156]	new[156]	_	_
18-19	3321-3333	relationship	abstract[156]	new[156]	_	_
18-20	3334-3341	between	abstract[156]	new[156]	_	_
18-21	3342-3345	the	abstract[156]|abstract[158]	new[156]|new[158]	_	_
18-22	3346-3349	two	abstract[156]|abstract[158]	new[156]|new[158]	_	_
18-23	3350-3364	quantification	abstract[156]|abstract|abstract[158]	new[156]|new|new[158]	_	_
18-24	3365-3372	methods	abstract[156]|abstract[158]	new[156]|new[158]	_	_
18-25	3373-3377	used	_	_	_	_
18-26	3378-3380	to	_	_	_	_
18-27	3381-3390	determine	_	_	_	_
18-28	3391-3401	leukotoxic	abstract[159]	giv[159]	_	_
18-29	3402-3411	potential	abstract[159]	giv[159]	_	_
18-30	3412-3414	as	abstract[159]	giv[159]	_	_
18-31	3415-3418	the	abstract[159]	giv[159]	_	_
18-32	3419-3423	LtxA	abstract[159]|abstract	giv[159]|giv	_	_
18-33	3424-3434	production	abstract[159]	giv[159]	_	_
18-34	3435-3438	and	abstract[159]	giv[159]	_	_
18-35	3439-3449	expression	abstract[159]	giv[159]	_	_
18-36	3450-3452	of	abstract[159]	giv[159]	_	_
18-37	3453-3455	A.	abstract[159]|person	giv[159]|giv	_	_
18-38	3456-3477	actinomycetemcomitans	abstract[159]	giv[159]	_	_
18-39	3478-3479	,	abstract[159]	giv[159]	_	_
18-40	3480-3492	respectively	abstract[159]	giv[159]	_	_
18-41	3493-3494	.	_	_	_	_
